Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Empresa Reclamada
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions leer más
I have only been with Karyopharm for less than 3 months, but I am very happy with my decision to join the team!
¿Qué es lo más positivo de la cultura y el ambiente de tu empresa?
The excitement associated with the expanded use of XPOVIO.
Revisión
¿Qué es lo que te hace más feliz en el trabajo?
Meeting the needs of the teams that I support. Trying to help them be more efficient.
Revisión
Other Employee Reviews for Karyopharm Therapeutics
×